Drug intelligence / Profile preview

Shaogan

Development stage: Phase 1
Lead developer: China Pharmaceutical Research & Development Center
Modality: Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration: Oral

Overview

Shaogan (Shaogan Tablet) is a botanical drug candidate developed by the China Pharmaceutical Research and Development Center Co., Ltd. for the treatment of primary dysmenorrhea. The formulation is derived from the traditional Chinese medicine (TCM) formula Shaoyao Gancao Tang, which is a combination of *Paeonia lactiflora* (white peony) and *Glycyrrhiza uralensis* (licorice). It is designed to alleviate menstrual cramps through its antispasmodic action on smooth muscle and its analgesic properties. Clinical development has reached Phase I in China, focusing on the safety, tolerance, and pharmacokinetic profile of the tablet in human subjects.

Other names: Shaogan Tablet芍甘片

Beyond the preview

Go deeper on Shaogan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shaogan.